What FDA Just Did and Why It Matters
The Federal Register notice published on October 30, 2026 (document 2026-22181) gives that path to a new category: the spinal imaging system for neuraxial procedures is now classified into class II with special controls, under 21 CFR part 868 (anesthesiology devices).
If you build imaging, navigation, or guidance technology for epidurals, spinal anesthesia, lumbar punctures, or similar needle-placement work, this is the notice to read in full. The special controls become the checklist FDA expects your premarket file to answer, and they will probably shape what your quality system has to show as well.
This article works from FDA's published summary of the action, which says the agency determined class II "will provide a reasonable assurance of the safety and effectiveness" of the device type. The codified identification and special controls are in the order itself, linked above, and that text is what governs.
What Is a Spinal Imaging System for Neuraxial Procedures?
Neuraxial procedures place a needle or catheter near the spinal cord and its surrounding spaces. Epidural and spinal anesthesia for surgery and labor are the most familiar examples, along with lumbar punctures and some pain interventions. Clinicians have traditionally relied on palpation of bony landmarks, sometimes supplemented by fluoroscopy or general-purpose ultrasound.
A spinal imaging system built for this purpose gives the clinician a view of spinal anatomy to help plan or guide needle placement. The exact intended-use language FDA adopted is in the order, and that language matters more than the label. In my view, the single most common regulatory mistake with a new device type is assuming your product fits the definition because it sounds similar. Compare your intended use statement against the codified identification word for word.
For context on how FDA has handled a neighboring ultrasound-related anesthesiology device, see our write-up on classification of real-time ultrasound guidance devices in anesthesiology.
What Does Class II with Special Controls Mean?
The FD&C Act sorts devices by risk. Class II, defined in section 513(a)(1)(B) (21 U.S.C. 360c(a)(1)(B)), applies when general controls alone cannot assure safety and effectiveness but there is enough information to establish special controls that can. Special controls are device-specific requirements, often performance testing, labeling, software documentation, or design requirements, written into the classification regulation.
The practical difference between the classes looks like this:
| Feature | Class I | Class II (this device) | Class III |
|---|---|---|---|
| Risk level | Lowest | Moderate | Highest |
| Controls | General controls | General controls plus special controls | General controls plus premarket approval |
| Typical premarket route | Usually exempt | 510(k), unless exempted | PMA |
| Predicate needed | No, because most Class I devices are exempt from premarket notification | Yes, for a 510(k) | No, because a PMA stands on its own clinical evidence |
The row that changes things for you is the predicate. Before this order, a spinal imaging system with no legally marketed predicate would typically have faced the De Novo pathway under section 513(f)(2). With the device type now classified, later sponsors can generally use the 510(k) pathway and cite the classified device as a predicate, provided they meet the special controls and show substantial equivalence. Whether FDA also exempted the device from premarket notification is addressed in the order, so check it before you plan a submission.
The De Novo Summary
The order's preamble should identify the De Novo grant, if any, that the classification codifies. Read that decision summary alongside the order: it typically sets out the risk analysis behind each control and shows how FDA reads them.
Effective Date and Deadlines
The order was published October 30, 2026. Final classification orders of this kind generally take effect on the date of publication, but confirm the effective date, any exemption from 510(k), and any transition provision in the document itself before you plan a submission.
What does have a calendar attached is the quality system side. FDA's Quality Management System Regulation, the amendment to 21 CFR part 820 published February 2, 2024, took effect on February 2, 2026. It incorporates ISO 13485:2016 by reference. Any manufacturer entering the market with this device type is therefore working under QMSR from day one, not under the older Quality System Regulation.
Where to Find the Special Controls
The special controls and the device identification are codified in the Federal Register order. Read them there and build your premarket file against that text, not against a summary or a generic imaging-device checklist.
Whether your device is ultrasound-based, uses another modality, or adds machine learning on top, check how the controls address performance evidence and software. For machine learning features specifically, our article on radiology machine learning device classification shows how FDA has approached similar questions.
How Should Manufacturers Respond?
I think the right sequence is to read the order, map your device against it, and only then decide on a regulatory strategy. Here is how I would work through it.
1. Confirm your device is in scope
Pull the device identification text and set your intended use statement next to it. Pay attention to the procedures named, the user, the anatomical region, and whether the system is guidance (during the procedure) or planning (before it). A gap between your claims and the identification can push you into a different classification, or back into De Novo.
2. Build a control-by-control traceability matrix
Each special control should map to a specific test report, design document, or labeling element. This is the same discipline you already apply under design controls, and QMSR makes it a quality system record as well. For a refresher on structuring that work, see our page on design controls.
3. Identify your predicate and plan the 510(k)
If an authorized device exists in this type, its public summary tells you what testing FDA accepted. Plan to show substantial equivalence on intended use and technological characteristics, and explain any differences with data. Our 510(k) overview covers the submission mechanics.
4. Tie risk management to the special controls
The special controls exist because FDA identified specific risks. In a neuraxial setting, the consequences of poor image guidance include misplaced needles, dural puncture, nerve injury, and bleeding, all of which belong in your ISO 14971:2019 hazard analysis. Show how each control reduces a named risk. Our guide on integrating ISO 14971 with ISO 13485 explains how to keep those records connected.
5. Check your quality system against QMSR
Because 21 CFR part 820 now incorporates ISO 13485:2016, auditors will look for design and development records (clause 7.3, which is where verification and validation of device software sits), planning of product realization including risk management (clause 7.1), validation of software used in the quality system (clause 4.1.6), and supplier controls (clause 7.4). Software-heavy imaging devices tend to expose weak spots in supplier controls and software records.
Common Mistakes to Avoid
- Treating the special controls as a menu. They are requirements, and a 510(k) that leaves one unaddressed invites an additional information request that costs months.
- Reusing general-purpose ultrasound clearance as proof for a neuraxial claim. A system cleared for broad diagnostic imaging has not necessarily been evaluated for guiding needle placement near the spinal canal, and the intended use is where FDA draws the line.
- Underestimating the labeling. When a clinician relies on an image to place a needle, the limitations section carries real safety weight. Poor visualization in patients with advanced spinal pathology or very high body mass index, if relevant to your device, belongs in plain language, not buried in an appendix. If the user alone decides what to do when image quality is poor, that is a use-related risk and belongs in your file.
Post-Market Obligations
Post-market obligations do not change with classification, but they matter more for novel technology. Complaint handling, medical device reporting under 21 CFR part 803, and corrections and removals under part 806 all apply. If you sell in the EU too, our article on post-market surveillance under ISO 13485 and EU MDR covers how to build one system that serves both.
Where to Start This Week
Read the order and the originating De Novo summary. Put your intended use next to the identification. Then list every special control and name the document in your file that answers it, and flag the ones where the answer is "we don't have that yet." That list is your real work plan, and it is usually shorter than people fear once it is written down.
If you want a second set of eyes on the gap list, you can reach me through Certify Consulting.
Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP Principal Consultant, Certify Consulting
Last updated: 2026-11-04
Frequently Asked Questions
What did FDA do with the spinal imaging system for neuraxial procedures?
FDA classified the device type into class II with special controls, in a Federal Register notice published October 30, 2026 (document 2026-22181). The special controls are part of the codified language in 21 CFR part 868.
Do I need a 510(k) for a spinal imaging system for neuraxial procedures?
Class II devices generally require a 510(k) unless FDA exempts them. With the device type classified, later sponsors can usually cite a classified device as a predicate instead of using De Novo. Check the order for any exemption language before planning your submission.
What are special controls?
Special controls are device-specific requirements written into a class II classification regulation, such as performance testing, software documentation, or labeling. They go beyond general controls and must be addressed in a premarket submission for the device type.
Does the QMSR apply to manufacturers of this device?
Yes. The Quality Management System Regulation amending 21 CFR part 820 took effect on February 2, 2026, and incorporates ISO 13485:2016 by reference. Manufacturers of this device type are subject to it.
Where can I find the exact special controls?
They are in the October 30, 2026 Federal Register order and will be codified in 21 CFR part 868. The originating De Novo decision summary on FDA's website usually explains the risk rationale behind each control.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.